title: DNA vaccination followed by macromolecular multicomponent peptide vaccination against HIV-1 induces strong antigen-specific immunity.
abstract: The induction of a strong and long-lasting immunity characterized by both a humoral and cell-mediated immune (CMI) response is one of the most important considerations in developing an effective HIV vaccine. In previous studies, we have independently developed both DNA vaccine and macromolecular multicomponent peptide vaccine (VC1) candidates. In the present study, we attempted to optimize the vaccination protocol using mice, guinea pigs, rabbits and Macaca fuscata monkeys. Repeated vaccination with VC1 induced a substantial level of multivalent antibodies which neutralized various HIV-1 strains, as determined using a p24 inhibition assay. On the other hand, repeated immunization with DNA vaccine induced and sustained high levels of cytotoxic T lymphocytes (CTLs). In addition, when DNA vaccination was followed by multicomponent peptide vaccination, levels of both humoral immunity and CMI increased, and this effect continued for at least 10 months. These data clearly demonstrate that for inducing HIV-1 specific immunity, immunization with DNA vaccine followed by VC1 boosting produces better results than immunizing with either vaccine alone.
authors.affiliation: Department of Bacteriology, Yokohama City University School of Medicine, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Okuda
authors.forename: K O
authors.initials: KO
authors.lastname: Xin
authors.forename: T
authors.initials: T
authors.lastname: Tsuji
authors.forename: H
authors.initials: H
authors.lastname: Bukawa
authors.forename: S
authors.initials: S
authors.lastname: Tanaka
authors.forename: W C
authors.initials: WC
authors.lastname: Koff
authors.forename: K
authors.initials: K
authors.lastname: Tani
authors.forename: K
authors.initials: K
authors.lastname: Okuda
authors.forename: K
authors.initials: K
authors.lastname: Honma
authors.forename: S
authors.initials: S
authors.lastname: Kawamoto
authors.forename: K
authors.initials: K
authors.lastname: Hamajima
authors.forename: J
authors.initials: J
authors.lastname: Fukushima
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000235:genetics; D000595:Amino Acid Sequence; D000818:Animals; D006168:Guinea Pigs; D015483:HIV Antibodies / Q000096:biosynthesis; D016655:HIV Core Protein p24 / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000235:genetics / Q000276:immunology; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D007111:Immunity, Cellular; D007117:Immunization, Secondary; D007074:Immunoglobulin G / Q000096:biosynthesis; D007371:Interferon-gamma / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D008251:Macaca; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000235:genetics / Q000276:immunology; D011817:Rabbits; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000235:genetics
chemical_list: D016915:AIDS Vaccines; D015483:HIV Antibodies; D016655:HIV Core Protein p24; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D007074:Immunoglobulin G; D010446:Peptide Fragments; D019444:Vaccines, DNA; D015847:Interleukin-4; D007371:Interferon-gamma